Ublituximab: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Removed parameters. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Chemicals that do not have a ChemSpider ID assigned | via #UCB_Category |
|||
Line 44: | Line 44: | ||
}} |
}} |
||
'''Ublituximab''' is an [[Immunotherapy#Immunomodulators|immunomodulator]]. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf |
'''Ublituximab''' is an [[Immunotherapy#Immunomodulators|immunomodulator]]. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf }}</ref> |
||
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>https://clinicaltrials.gov/ct2/show/NCT03277261</ref> |
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>https://clinicaltrials.gov/ct2/show/NCT03277261</ref> |
Revision as of 04:37, 12 September 2020
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in Phase 2 clinical trials for chronic lymphocytic leukemia.
See also
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ https://clinicaltrials.gov/ct2/show/NCT03277261